NCT03311659View on ClinicalTrials.gov

Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

448

Participants

Timeline

Start Date

January 26, 2018

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Diphtheria-Tetanus-acellular Pertussis Vaccines
Interventions
BIOLOGICAL

Boostrix

One dose administered intramuscularly in the deltoid muscle of the non-dominant arm in dTap group.

Trial Locations (8)

115478

GSK Investigational Site, Moscow

129515

GSK Investigational Site, Moscow

150051

GSK Investigational Site, Yaroslavl

183038

GSK Investigational Site, Murmansk

188300

GSK Investigational Site, Gatchina

191025

GSK Investigational Site, Saint Petersburg

620137

GSK Investigational Site, Yekaterinburg

656056

GSK Investigational Site, Barnaul

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY